KDC-MN-211 – Kodiac biolabs

Plain-language summaryIntrigue 64 / 100

Trazodone is an old antidepressant from 1981 that almost nobody uses for depression anymore, because at the doses needed for mood (300 to 600 mg) it is unpleasantly sedating. What it gets prescribed for instead, by enormous margins, is sleep. At 25 to 100 mg it acts as a clean hypnotic by blocking the histamine receptor and the 5-HT2A serotonin receptor, both of which promote arousal. It is non-controlled, has no dependence potential, does not produce the next-day cognitive hangover of older sleep drugs, and is preferred for older adults specifically because it lacks the fall risk of benzodiazepines. The active leftover mCPP is a serotonin receptor activator that occasionally causes brief mood disturbance. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

40/100

A 45-year-old approved hypnotic with one genuinely interesting neurodegeneration research angle that doesnt move the needle much

Look, trazodone is a compound thats easy to understand and hard to get excited about from a research frontier perspective. Approved by FDA in 1981, its been sitting in the formulary for over four decades as an antidepressant that nobody uses as a first-line antidepressant anymore. What it became is a sleep aid, and thats mostly because its 5-HT2A and H1 antagonism at low dose produces useful sedation without the dependency profile that comes with GABAergic hypnotics. That pharmacological angle is real, well-documented, and thoroughly exhausted as a research question.

The SARI mechanism itself is fine but unremarkable. The weak SERT inhibition (Ki around 160 nM) is why its not competitive with modern SSRIs. The H1 and 5-HT2A hit is why it works as a sleep agent. The active metabolite mCPP is a 5-HT2C agonist that explains some of the anxiogenic side effects some subjects report, and thats a mildly interesting pharmacological wrinkle but again not frontier territory. If you need a 5-HT2A antagonist tool compound, ketanserin is more selective and better characterized for that specific purpose.

Heres the one thing that keeps this from scoring lower than it does. In 2017 Mallucci’s group at the MRC Toxicology Unit published in Brain showing trazodone and dibenzoylmethane could restore protein synthesis in prion disease and other neurodegenerative models by activating eIF2B, essentially bypassing the phospho-eIF2alpha block in the integrated stress response. That finding was not trivial. The ISR pathway is a genuinely active research space for neurodegeneration, and trazodone turned out to be a tool compound for studying it. There’s been follow-up work and some early phase 2 signals in frontotemporal dementia. We think this is real biology. But the evidence base for this specific angle is still small, dominated by that group, and trazodone itself may not be the optimal probe for the ISR pathway going forward.

From a bench utility standpoint, trazodone sits in a weird middle space. Its too well-characterized to be interesting as a novel object of study, but its not indispensable as a research tool the way rapamycin is to mTOR work or ketamine is to NMDA biology. The hypnotic use case is settled science. The ISR angle is interesting but early and contested in terms of whether trazodone is the right vehicle to pursue that biology. What we dont like here is that a serious investigator studying either sleep pharmacology or the ISR pathway would almost certainly reach for different compounds first. The translational signal is solid because its an approved drug that demonstrably works, but that same approval status tells you the research questions around it were answered decades ago.

Novelty: 18
Mechanism promise: 35
In-category differentiation: 28
Evidence quality: 68
Translational signal: 65
Research bench value: 42

Rationale Trazodone scores well on translational signal and evidence because its an approved drug with a massive clinical base, but those same facts kill novelty and differentiation; the one legitimately interesting research angle (ISR/eIF2B activation in neurodegeneration, Mallucci group 2017 Nature) is intriguing but thin on replication and doesnt define a broader research program around trazodone specifically.

Serotonin antagonist and reuptake inhibitor (SARI)

A triazolopyridine antidepressant repurposed at low dose as a hypnotic via potent H1 and 5-HT2A antagonism.

Abstract

Trazodone (2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one; CAS 19794-93-5; molecular formula C19H22ClN5O; molecular weight 371.86) is a triazolopyridine SARI developed at Angelini and approved by the FDA in 1981. The compound is a weak SERT inhibitor (Ki approximately 160 nM) but a potent 5-HT2A and H1 antagonist (5-HT2A Ki approximately 36 nM, H1 Ki approximately 220 nM). The active metabolite mCPP (m-chlorophenylpiperazine) is a 5-HT2C agonist contributing to anxiogenic side effects in some patients. Pharmacological profile distinguishes trazodone from SSRIs: at antidepressant doses (150 to 600 mg daily) the SERT inhibition contributes meaningfully, but at the more common hypnotic doses (25 to 100 mg) the H1 and 5-HT2A antagonism dominates, producing pronounced sedation without the GABAergic dependency profile of benzodiazepine hypnotics. Plasma half-life is bimodal: 3 to 6 hours alpha phase, 5 to 9 hours beta phase. Adverse events include orthostatic hypotension and the rare but serious priapism (1 in 1000 to 1 in 10000 incidence). Used as a low-dose hypnotic and as a reference compound for 5-HT2A receptor pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-211Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-211

Trazodone

Abstract

Read the full monograph